26.98
0.81 (3.10%)
| Penutupan Terdahulu | 26.17 |
| Buka | 26.31 |
| Jumlah Dagangan | 530,421 |
| Purata Dagangan (3B) | 661,195 |
| Modal Pasaran | 2,004,689,280 |
| Harga / Jualan (P/S) | 18.73 |
| Harga / Buku (P/B) | 7.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -121.73% |
| Margin Operasi (TTM) | -94.48% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 170.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.68% |
| Nisbah Semasa (MRQ) | 4.71 |
| Aliran Tunai Operasi (OCF TTM) | -75.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.20 M |
| Pulangan Atas Aset (ROA TTM) | -13.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -29.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Zymeworks Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.13 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 102.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bnp Paribas Asset Management Holding S.A. | 31 Dec 2025 | 1,822,048 |
| Deutsche Bank Ag\ | 31 Dec 2025 | 1,595,833 |
| Capricorn Fund Managers Ltd | 31 Dec 2025 | 1,022,840 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 865,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 58.00 (Leerink Partners, 114.97%) | Beli |
| Median | 47.50 (76.06%) | |
| Rendah | 46.00 (HC Wainwright & Co., 70.50%) | Beli |
| Purata | 49.75 (84.40%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 24.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Evercore ISI Group | 09 Mar 2026 | 48.00 (77.91%) | Beli | 24.25 |
| HC Wainwright & Co. | 06 Mar 2026 | 46.00 (70.50%) | Beli | 24.08 |
| Leerink Partners | 03 Mar 2026 | 58.00 (114.97%) | Beli | 24.45 |
| Stifel | 03 Mar 2026 | 47.00 (74.20%) | Beli | 24.45 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Zymeworks Announces Participation in Upcoming Investor Conferences |
| 27 Jan 2026 | Pengumuman | Zymeworks Announces Participation in Upcoming Investor Conferences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |